John Kelley
Chairman presso ACORDA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
John P.
Kelley was the founder of Phyxius Pharma, Inc. (founded in 2011) where he held the title of President, Chief Executive Officer & Director from 2011 to 2013.
He is currently working as a Non-Executive Chairman at Acorda Therapeutics, Inc. since 2008.
In his former positions, Mr. Kelley served as the Chief Executive Officer & Director at Tenax Therapeutics, Inc. from 2013 to 2017, Vice President & Commercial Director-US at Hoechst Marion Roussel, Inc. from 1995 to 1999, Vice President-Marketing at Hoechst Marion Roussel SA in 1999, President & Chief Operating Officer at The Medicines Co. from 2004 to 2009, and Senior Vice President-Global Marketing & Medical at Aventis Pharmaceuticals, Inc. from 2000 to 2004.
Mr. Kelley obtained an MBA from Rockhurst University and an undergraduate degree from Wilkes University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 24/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di John Kelley
| Società | Posizione | Inizio |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | Chairman | 25/11/2019 |
Precedenti posizioni note di John Kelley
| Società | Posizione | Fine |
|---|---|---|
| TENAX THERAPEUTICS, INC. | Chief Executive Officer | 03/04/2017 |
Phyxius Pharma, Inc.
 Phyxius Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Tenax Therapeutics, Inc., Phyxius Pharma, Inc. provides pharmaceutical products. The private company is based in Chester, NJ. The company was founded by Doug Randall, Douglas Hay, John P. Kelley. Phyxius Pharma was acquired by Life Newco, Inc. on November 13, 2013 for $32.66 million. | Founder | 13/11/2013 |
| THE MEDICINES COMPANY | President | 01/10/2009 |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | 01/09/2004 |
| Hoechst Marion Roussel SA | Sales & Marketing | 01/12/1999 |
Formazione di John Kelley
| Rockhurst University | Masters Business Admin |
| Wilkes University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| TENAX THERAPEUTICS, INC. | Health Technology |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
| Hoechst Marion Roussel SA | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
| Hoechst Marion Roussel, Inc. | |
Phyxius Pharma, Inc.
Phyxius Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Tenax Therapeutics, Inc., Phyxius Pharma, Inc. provides pharmaceutical products. The private company is based in Chester, NJ. The company was founded by Doug Randall, Douglas Hay, John P. Kelley. Phyxius Pharma was acquired by Life Newco, Inc. on November 13, 2013 for $32.66 million. | Health Technology |
- Borsa valori
- Insiders
- John Kelley
